• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤疫苗的最新进展。

Update on tumor vaccines.

作者信息

Stevenson F K

机构信息

Molecular Immunology Group, Southampton University Hospitals, UK.

出版信息

Int J Clin Lab Res. 1992;22(2):84-9. doi: 10.1007/BF02591402.

DOI:10.1007/BF02591402
PMID:1504310
Abstract

Vaccination against tumor has always been an attractive idea for the treatment of patients bearing tumor. By harnessing the host's own immune response the attack on tumor cells would act on a continuing basis, with emerging tumor cells stimulating their own destruction. However, the approach has been hampered by our poor understanding of the nature of tumor antigens and of the pathways by which immune cells might operate against tumor growth. Recent developments in molecular biology and immunology are remedying this deficiency and bringing vaccination to the forefront of new approaches to treatment of a range of tumors. Results obtained in B-cell tumors, where the idiotypic immunoglobulin at the cell surface provides a well-defined tumor antigen, are already indicating exciting possibilities as well as delineating problems. There is considerable clinical evidence that patients have some intrinsic ability to control tumor growth and that certain tumors remain dormant for long periods. Attempts to understand and perhaps stimulate the mechanisms involved are being made through the use of biological modifiers and by manipulating potential effector cells in vitro. Ideally this approach, which may include non-specific and specific elements, could be combined with specific vaccination in order to combat the apparent ability of many tumor cells to evade host defences.

摘要

肿瘤疫苗接种一直是治疗肿瘤患者的一个颇具吸引力的想法。通过利用宿主自身的免疫反应,对肿瘤细胞的攻击将持续进行,新出现的肿瘤细胞会刺激自身被破坏。然而,由于我们对肿瘤抗原的性质以及免疫细胞对抗肿瘤生长可能采用的途径了解不足,这种方法受到了阻碍。分子生物学和免疫学的最新进展正在弥补这一缺陷,并使疫苗接种成为一系列肿瘤新治疗方法的前沿手段。在B细胞肿瘤中获得的结果已经显示出令人兴奋的可能性,同时也明确了问题,在B细胞肿瘤中,细胞表面的独特型免疫球蛋白提供了一个明确的肿瘤抗原。有大量临床证据表明,患者具有一定的内在控制肿瘤生长的能力,并且某些肿瘤会长期处于休眠状态。人们正在通过使用生物调节剂以及在体外操纵潜在的效应细胞来尝试理解并可能刺激其中涉及的机制。理想情况下,这种可能包括非特异性和特异性成分的方法可以与特异性疫苗接种相结合,以对抗许多肿瘤细胞逃避宿主防御的明显能力。

相似文献

1
Update on tumor vaccines.肿瘤疫苗的最新进展。
Int J Clin Lab Res. 1992;22(2):84-9. doi: 10.1007/BF02591402.
2
Strategies for immunotherapy of cancer.癌症免疫治疗策略。
Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1.
3
A genetic approach to idiotypic vaccination for B cell lymphoma.一种针对B细胞淋巴瘤的独特型疫苗接种的遗传学方法。
Ann N Y Acad Sci. 1995 Nov 27;772:212-26. doi: 10.1111/j.1749-6632.1995.tb44747.x.
4
Idiotypic responses induced by tumor: an autocrine network.肿瘤诱导的独特型反应:一种自分泌网络。
Int Rev Immunol. 1989;4(4):311-20. doi: 10.3109/08830188909044784.
5
Tumor vaccines.
FASEB J. 1991 Jun;5(9):2250-7. doi: 10.1096/fasebj.5.9.1860616.
6
Prospects for the treatment of B cell tumors using idiotypic vaccination.
Int Rev Immunol. 1989;4(4):271-310. doi: 10.3109/08830188909044783.
7
Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.肿瘤排斥抗原与肿瘤特异性细胞毒性T淋巴细胞。
Behring Inst Mitt. 1994 Jul(94):72-86.
8
Tumor immunology.肿瘤免疫学
Immunol Ser. 1993;58:497-515.
9
Tumor immunology.
Curr Opin Oncol. 1991 Feb;3(1):93-9. doi: 10.1097/00001622-199102000-00013.
10
Idiotypic interactions in immune responses to tumor-associated antigens.
Biochim Biophys Acta. 1986 Oct 28;865(2):127-39. doi: 10.1016/0304-419x(86)90025-9.

引用本文的文献

1
Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice.脂质体包裹的肿瘤相关抗原诱导小鼠对SL2淋巴瘤细胞产生保护性肿瘤免疫的关键因素。
Cancer Immunol Immunother. 1993 Sep;37(4):271-9. doi: 10.1007/BF01518522.